Trial reportAdvances in therapy2026
Clinical Remission with FF/UMEC/VI Versus ICS/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial.
Trial report in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06372496 (A Phase 4, 52-week), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 4, 52-week (Primary Analysis at 24-weeks), Randomized, Stratified, Open-label, Active-controlled, Parallel-group, Effectiveness Study, Comparing FF/UMEC/VI With Non-ellipta Usual Care (ICS/LABA) in Adult Participants With Uncontrolled Asthma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionProspective, randomized evidence for clinical remission, an ambitious treatment goal relevant for all patients with asthma, with single-inhaler triple therapy (SITT) in routine care is lacking. Significant improvement in lung function and asthma control with SITT versus inhaled corticosteroid/long-acting β
methodsPERFORM (GSK 219912/NCT06372496), a randomized, open-label, active-controlled, global pragmatic trial, evaluated the effectiveness and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus usual care ICS/LABA in adults (18-75 years) with uncontrolled, infrequently exacerbating asthma. Secondary outcomes related to clinical remission (no oral corticosteroid use, no severe exacerbations, optimized lung function [change from baseline (CFB) in forced expiratory volume in 1 second (FEV
resultsOverall, 1236 participants (mean age 48.9 years; 68.6% [n = 848/1236] female) were included (FF/UMEC/VI: N = 619/1236; ICS/LABA: N = 617/1236). Participants receiving FF/UMEC/VI had statistically significantly greater odds of achieving clinical remission (including optimized lung function) at week 52 versus usual care ICS/LABA (adjusted odds ratio [95% confidence interval] 2.13 [1.54, 2.94], P < 0.0001). Similar results were observed for alternative definitions. Week 52 safety profile aligned with previous studies.
conclusionsIn a broad patient population with uncontrolled asthma, treatment with FF/UMEC/VI resulted in statistically significantly greater odds of achieving clinical remission versus usual care ICS/LABA in a setting reflecting routine practice, a secondary outcome of PERFORM. These findings were consistent irrespective of clinical remission definitions and provide evidence informing the use of FF/UMEC/VI in an underserved group of symptomatic patients with infrequent exacerbations and minimal lung function impairment.
trial registrationGSK 219912/NCT06372496.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.